Cocrystal Pharma Adds Antiviral Veteran Carol Brosgart to Board
Event summary
- Cocrystal Pharma appointed Carol Brosgart, MD, to its Board of Directors on August 12, 2026.
- Dr. Brosgart brings decades of experience in antiviral therapy, epidemiology, and biopharma advisory.
- She played a critical role in the development and regulatory approval of Gilead's Viread® and Hepsera®.
- Dr. Brosgart currently serves on the boards of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech.
The big picture
Cocrystal Pharma's appointment of Carol Brosgart underscores its focus on strengthening governance with deep antiviral expertise. Brosgart's background in developing FDA-approved therapies and her extensive board experience align with Cocrystal's push to advance its clinical-stage antiviral pipeline. This move comes as the biotech sector faces increasing pressure to deliver effective treatments amid growing global health challenges.
What we're watching
- Pipeline Acceleration
- How Dr. Brosgart's expertise will impact the clinical development of CDI-988 for norovirus and the broader antiviral pipeline.
- Regulatory Insight
- Whether her experience with FDA approvals can streamline Cocrystal's regulatory pathways.
- Strategic Governance
- The pace at which her advisory role influences Cocrystal's long-term strategic direction.
Related topics